FindTrial
Sign In

To study the positive effect of Sidenafil on quality of life and exercise capacity in heart disease patients

To study the effect of Sildenafil on exercise capacity, quality of life and hemodynamics in patients with biventricular dysfunction with secondary pulmonary hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011335
Enrollment
50
Registered
2018-01-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients suffering from chronic heart disease

Interventions

Intervention1: Sildenafil: sildenafil is a phosphodiesterase 5 inhibitor and primarily used as selective pulmonary vasodilator in cardiovascular disease Control Intervention1: Placebo: Multivitamin t

Sponsors

NONE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age >18yrs 2.Patients with BIVENTRICULAR DYSFUCTION i.e ( LVSF and RVSF 3.Patients on optimal maximal medical therapy 4.Reversible causes of cardiomyopathy ruled out 5.Non revascularizable CAD( on basis of viability testing or coronary vessels not suitable for PTCA or grafting)

Exclusion criteria

Exclusion criteria: Patients with other associated co morbidities which affect the pulmonary artery pressure and RVEF like COPD, connective tissue disorder, CTEP, valvular heart disease, OSA

Design outcomes

Primary

MeasureTime frame
Improvement in right ventricular hemodynamicsTimepoint: from baseline to 6 months followup—

Secondary

MeasureTime frame
improvement in physical quality of lifeTimepoint: from baseline to 6 months followup—

Countries

India

Contacts

Public ContactVikas Kadiyala

PGIMER

ypspgi@gmail.com9417167214

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026